· Published by Health Canada · Official notice
This is duplicated text of a letter from Baxter Corporation. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
September 19, 2014
Dear Health Care Professional,
Subject: Urgent Product Recall for Two (2) Lots of Acid Concentrate 45X (45 K, 67.5 Ca) 4.5L (DIN 02158256) and Acid Concentrate 45X (45 K, 45.0 Ca) 4.5L (DIN 00860611) due to particulate matter
Baxter Corporation in consultation with Health Canada would like to inform you that Baxter has initiated a recall of two (2) lots of concentrated hemodialysis solution, Acid Concentrate 45X (45K, 67.5 Ca) and Acid Concentrate 45X (45K. 45.0Ca), due to particulate matter identified along the solution rim. There is potential for patient injury. These lots were distributed in Canada between January 31, 2014 and July 18, 2014.
Baxter is recalling the following two (2) lots.
Acid Concentrate 45X (45K, 67.5Ca) Product Code: D12255M Lot No: W4D17D1
Acid Concentrate 45X (45K, 45.0Ca) Product Code: D12188M Lot No: W4A24D1
The specified Acid Concentrate Hemodialysis Solution lots should not be used. Contact Baxter Customer Care to arrange for return and credit of the affected lot numbers at 1-888-719-9955. Baxter is currently investigating this issue and has not received any reports of adverse events for the specified lots.
Acid Concentrate hemodialysis solution is proportioned with Bicarbonate concentrate and purified water to produce dialysate.
Repeated ineffective solute clearance can result in patient symptoms including weakness, tiredness, lack of energy, shortness of breath and mental status changes. Particulate matter passing into the dialysis patient’s blood stream may result in serious patient injury, such as an allergic response, and/or an embolic event.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving Concentrated Hemodialysis Solutions should be reported to Baxter Corporation or Health Canada.
Baxter Corporation
Mailing address:
Attn: Pharmacovigilance
7125 Mississauga Road
Mississauga, ON
L5N 0C2
Phone: 1-800-387-8399 ext 6607
E-Mail: canada_pharmacovigilance@baxter.com
Fax: 1-855-767-4573
To correct your mailing address or fax number, contact Baxter Customer Care at 1-888-719-9955.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, contact Health Canada at:
Health Products and Food Branch Inspectorate
E-mail: DCVIU_UVCEM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 613-946-5636
Sincerely,
original signed by
Danielle Tokarski
Quality Systems Manager
Baxter Corporation